Gilead Sciences Inc. (GILD)

80.70
NASDAQ : Health Technology
Prev Close 81.55
Day Low/High 80.61 / 82.33
52 Wk Low/High 63.76 / 89.54
Avg Volume 8.43M
Exchange NASDAQ
Shares Outstanding 1.31B
Market Cap 104.68B
EPS 3.50
P/E Ratio 9.23
Div & Yield 2.28 (2.54%)

Latest News

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ACXM, ADM, APC, IT, NOV, PXD, TPR, VSM Downgrades: AGX, CMCO, CMI, FARM, FFWM, GILD, GLAD, GRAM, HAE, KT, MLI, MLP, RRTS, UDR, USNA, VSH Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

Gilead Sciences Announces 10 Percent Increase In First Quarter 2018 Dividend

Gilead Sciences Announces 10 Percent Increase In First Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 10% in the company's quarterly cash dividend, beginning in the first quarter of 2018.

Gilead Sciences Announces Fourth Quarter And Full Year 2017 Financial Results

Gilead Sciences Announces Fourth Quarter And Full Year 2017 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2017.

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

Maybe inverse and/or leveraged positions are perverse in nature.

Jacqueline K. Barton, Ph.D., Joins Gilead Sciences' Board Of Directors

Jacqueline K. Barton, Ph.D., Joins Gilead Sciences' Board Of Directors

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jacqueline K.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Cramer: Step Away and Get Your Clients Better Prices

Cramer: Step Away and Get Your Clients Better Prices

You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Gilead Sciences To Release Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 6, 2018

Gilead Sciences To Release Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 6, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 6, after the market closes.

Celgene Could Be Bulking Up Very Fast

Celgene Could Be Bulking Up Very Fast

The biopharmaceutical company, whose biggest acquisition to date was Receptos in 2015 for $7.2 billion, recently agreed to pay up to $7 billion for Impact Biomedicines and reportedly is in talks for Juno, an immunotherapy company.

Kite Announces Clinical Collaboration To Evaluate Investigational Combination Of Yescarta™ (Axicabtagene Ciloleucel) And Pfizer's Utomilumab In Large B-Cell Lymphoma

Kite Announces Clinical Collaboration To Evaluate Investigational Combination Of Yescarta™ (Axicabtagene Ciloleucel) And Pfizer's Utomilumab In Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced it has entered into a clinical trial collaboration with Pfizer, Inc.

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Healthcare executives meeting at JP Morgan Conference agree that new tax reform is good, but how it will impact the sector is not yet entirely clear.

See How Gilead Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Gilead Sciences Inc is the #53 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Gilead Sciences To Present At The 36th Annual J.P. Morgan Healthcare Conference On Monday, January 8

Gilead Sciences To Present At The 36th Annual J.P. Morgan Healthcare Conference On Monday, January 8

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the 36 th Annual J.

Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman To Chairman Of The Board Of Directors

Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman To Chairman Of The Board Of Directors

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Executive Chairman John Martin, PhD will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.

4 Signs the Bull Market in Stocks Remains Incredibly Strong

4 Signs the Bull Market in Stocks Remains Incredibly Strong

Growth is here to stay, and value is for more than just the old strongholds.

Kite Announces Data From ZUMA-3 Study Of KTE-C19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite Announces Data From ZUMA-3 Study Of KTE-C19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company (Nasdaq: GILD), announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, which is investigational for the treatment of...

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta™ (Axicabtagene Ciloleucel) In Patients With Refractory Large B-cell Lymphoma

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta™ (Axicabtagene Ciloleucel) In Patients With Refractory Large B-cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

Erytech Pharma Plummets on Phase 2 Data -- Biotech Movers

Erytech Pharma Plummets on Phase 2 Data -- Biotech Movers

France-based firm said its Phase 2 study of eryaspase (Graspa) in acute myeloid leukemia did not achieve its primary endpoint of overall survival.

Gilead Sciences And Kite To Acquire Cell Design Labs

Gilead Sciences And Kite To Acquire Cell Design Labs

Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc.

Gilead Announces 10-Year, $100 Million Commitment To Address The HIV/AIDS Epidemic In The Southern United States

Gilead Announces 10-Year, $100 Million Commitment To Address The HIV/AIDS Epidemic In The Southern United States

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the launch of the Gilead COMPASS ( COM mitment to P artnership in A ddressing HIV/AIDS in S outhern S tates) Initiative, a 10-year, $100 million commitment...

TheStreet Quant Rating: C (Hold)